About Bio-Path Holdings
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Delivery
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: BPTH
- Previous Close: $0.95
- 50 Day Moving Average: $1.0012
- 200 Day Moving Average: $1.2640
- 52-Week Range: $95,645,000.00 - $0.81
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.62
- P/E Growth: 0.0000
- Market Cap: $90.66M
- Outstanding Shares: 95,645,000
- Beta: 2.64
- Return on Equity: -81.94%
- Return on Assets: -68.25%
Companies Related to Bio-Path Holdings:
- Current Ratio: 14.42%
- Quick Ratio: 14.42%
What is Bio-Path Holdings' stock symbol?
Bio-Path Holdings trades on the NASDAQ under the ticker symbol "BPTH."
Where is Bio-Path Holdings' stock going? Where will Bio-Path Holdings' stock price be in 2017?
2 equities research analysts have issued 12 month price objectives for Bio-Path Holdings' shares. Their predictions range from $2.00 to $5.00. On average, they expect Bio-Path Holdings' share price to reach $3.50 in the next year.
When will Bio-Path Holdings announce their earnings?
Bio-Path Holdings is scheduled to release their next quarterly earnings announcement on Tuesday, March, 14th 2017.
What are analysts saying about Bio-Path Holdings stock?
Here are some recent quotes from research analysts about Bio-Path Holdings stock:
According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (1/11/2017)
Maxim Group analysts commented, "Bio-Path presented BP1001 (Liposomal Grb2 Antisense) data as a poster presentation titled Phase I Study of BP1001 (Liposomal Grb2 Antisense) in Patients with Hematologic Malignancies" at ASCO. The data included results from the Phase I study of BP1001 for the treatment of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), and safety data from the Phase II study of BP1001 in combination with low-dose cytarabine (LDAC) for advanced AML. The poster was presented by Dr." (6/6/2016)
Who owns Bio-Path Holdings stock?
Bio-Path Holdings' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.13%) and Raymond James Financial Services Advisors Inc. (0.81%).
Who sold Bio-Path Holdings stock? Who is selling Bio-Path Holdings stock?
Bio-Path Holdings' stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc..
Who bought Bio-Path Holdings stock? Who is buying Bio-Path Holdings stock?
Bio-Path Holdings' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp.
How do I buy Bio-Path Holdings stock?
Shares of Bio-Path Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Bio-Path Holdings stock cost?
One share of Bio-Path Holdings stock can currently be purchased for approximately $0.95.